Overview

SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Status:
RECRUITING
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SON-DP in Subjects with Advanced Solid Tumors
Phase:
PHASE1
Details
Lead Sponsor:
Qurgen Inc.